RNA-seq immune subtyping to optimize immunotherapy in mNSCLC

Discovery of molecular signatures that stratify real-world survival in lung cancer

INDICATION
Lung
BIOMARKER
TIGIT

 

2-year real-world overall survival in non-squamous NSCLC patients anchored on start of first line anti-PD-(L)1 + chemotherapy initiation. All patients censored at 2 years of follow-up.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Grid displaying data points with blue, black, and gray squares on a white background.

RB1 loss-of-function mutations in post-Osimertinib NSCLC and prognostic implications

2026-07-01
Lung
RB1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of small blue, gray, black, and orange squares on a white background.

Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma

2026-07-01
Lung
PPM1D
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Pixelated diagonal gradient with bands of purple, blue, and green dots, resembling data visualization.

PRAME expression and histology impact survival in first-line NSCLC

2026-05-26
Lung
PRAME